LIFESTYLE
NHS Misses the 62-Day Cancer Target as Patients Wait Twice
England’s 62-day cancer rate is 70.7%, and the 28-day clock is being met for all-clears, not for the patients who actually have cancer.
England treated 70.7% of cancer patients within 62 days in September, 9.3 points short of an 80% goal set for March 2027. NHS England published the figure on 12 November, down from 71.9% in August. Radiotherapy UK, working from those official counts, says 2,850 extra on-time starts are needed each month and that 9,490 patients will miss the staging post if volumes stay put.
The people inside that miss are not the crowd ministers cite when they say diagnosis is improving. In the 12 months to September, 79.1% of urgent referrals that ended in an all-clear were told within 28 days. Only 55.4% of those told they had cancer heard in time, then joined a treatment queue the NHS is still not staffing.
A 9.3-Point Hole in the 62-Day Standard
NHS England’s statistical release for September recorded that 70.7% began first treatment within 62 days of an urgent suspected-cancer referral, a breast symptomatic referral, an urgent screening referral or a consultant upgrade. The operational standard on that clock is 85%. The 80% figure due in March 2027 is an interim planning milestone for every trust, not the constitutional target.
September also moved the other two cancer clocks the wrong way. The 28-day Faster Diagnosis Standard, which asks that 80% of people are told they have cancer or that it has been ruled out, fell to 76.2% from 78.6% in August. The 31-day standard, from a decision to treat to first or later treatment, fell to 91.5% from 92.1%, against a 96% target.
THE THREE CANCER CLOCKS IN SEPTEMBER
| Standard | September | August | Target | 12-month average |
|---|---|---|---|---|
| 28-day Faster Diagnosis | 76.2% | 78.6% | 80% | 77.5% |
| 31-day treatment | 91.5% | 92.1% | 96% | 92.1% |
| 62-day referral to treatment | 70.7% | 71.9% | 85% (80% by March 2027) | 70.4% |
Those 12-month averages are the numbers a Department of Health and Social Care spokesperson can honestly call better than a year earlier. The 62-day rate averaged 70.4% from October 2025 to September 2026, up from 69.0% in the year before. The 28-day rate averaged 77.5%, up from 76.5%. The 31-day rate averaged 92.1%, up from 91.3%.
Volume rose with the dip. NHS England counted 30,522 treatments on the 62-day measure in September, up from 27,909 in August, and 300,367 Faster Diagnosis referrals, up from 273,664. A busier month made a soft 12-month climb look like a stall. It did not close a 9.3-point hole.
Only 55.4% of Cancer Diagnoses Arrive Within 28 Days
The Faster Diagnosis Standard is one number covering two very different outcomes, and the combined rate hides which group is waiting. Cancer Research UK’s split of the same official series found that 55.4% received their diagnosis within 28 days in the 12 months to September. That is a 0.4-point rise on the previous year and 24.6 points short of 80%. Among people who had cancer ruled out, 79.1% were told in time, up 1.1 points.
WHO CLEARS THE 28-DAY CLOCK
- Cancer diagnosed: 55.4% were told within 28 days in the 12 months to September, a 0.4-point rise year on year.
- Cancer ruled out: 79.1% heard in time, a 1.1-point rise that is carrying the overall rate.
- Missed results: About 25,400 people with cancer would have had their diagnosis sooner if the 80% standard had been met for that group since the target rose.
- Head and neck split: 35.9% of those later diagnosed were told in 28 days, against 78.9% of all-clears on the same pathway.
The Faster Diagnosis target itself rose from 75% to 80% on 1 April 2026. Combined performance can look close to that line because most urgent referrals do not end in cancer. Naser Turabi, Cancer Research UK’s director of health policy and evidence, puts the share who go on to a cancer diagnosis at 6%, and said hospital capacity has not kept pace with demand, with urgent referrals in England up about 20% over four years. The 290,000 extra on-time diagnoses or all-clears the health department cites against the year before the election are heavily weighted toward the larger group.
Waiting to find out whether you have cancer or not can be agonising. These figures show that those who ultimately receive the devastating news of a cancer diagnosis aren’t finding out quickly enough. On top of that emotional strain, people are being dealt a double blow as delays to diagnosis risk delays to getting vital treatment.
Michelle Mitchell, chief executive, Cancer Research UK
Dr Hilary Williams, clinical vice-president of the Royal College of Physicians and a consultant in medical oncology, said earlier diagnosis only helps if treatment then starts quickly, and that the NHS needs imaging, endoscopy and pathology staff plus enough surgery, radiotherapy and drug treatment so a faster test does not push the wait further down the path. The 31-day rate, once a decision to treat has already been made, sits much nearer its target than the 62-day rate. The time being lost is the stretch before that decision, which is the stretch where people who do have cancer are already failing the 28-day clock.
Head and Neck Pathways Trail Every Other Cancer
Radiotherapy UK’s reading of the September files shows the national 70.7% is an average of unequal waits. Prostate and breast pathways, which have screening routes and large, relatively standardised services, ran at 70.1% and 68.8%. Lung sat at 60.9%. Gynaecological cancers sat at 60%. Head and neck, already the site with the widest 28-day gap between a cancer diagnosis and an all-clear, sat at 56.5% on the 62-day clock.
62-DAY RATES BY CANCER TYPE, SEPTEMBER
| Cancer type | Treated within 62 days |
|---|---|
| All cancers | 70.7% |
| Prostate | 70.1% |
| Breast | 68.8% |
| Lung | 60.9% |
| Gynaecological | 60% |
| Head and neck | 56.5% |
Prof Pat Price, chair of Radiotherapy UK and an oncologist, said the government will miss the treatment target because the NHS does not have enough staff or equipment for the patients coming through the door, and that this lack of leadership means thousands more people could die because they do not get treatment on time.
Prostate and Breast Sit Closer to the Line
Those two sites still miss 80%, but they are not where the 9,490-patient hole is being dug. Head and neck patients are failing the 28-day test at 35.9% when the result is cancer, then failing the 62-day test at 56.5% when treatment should start. Lung and gynaecological pathways sit in the same band. A national rate in the low 70s can be read as slow progress. A head and neck rate in the mid-50s is a different service.
London Treats 77.3%, the Midlands 66.6%
The regional spread is as wide as the site spread. London treated 77.3% of patients within 62 days. The Midlands treated 66.6%, a 10.7-point gap. Between them sat the North-west at 72.9%, the South-east at 72.5%, the North-east and Yorkshire at 69.8%, the South-west at 69.3% and the East of England at 68.5%. Mark Lawler, professor of digital health at Queen’s University Belfast, said the system is being held together by goodwill, and that without accountability, a change in mindset and a focus on the basics, treatment targets will be missed for another decade.
Cancer Centres Doubled Recruitment Freezes in a Year
The second-order bind is that the same trusts being asked to pull 70.7% up to 80% spent 2025 blocking the hires that would do it. The Royal College of Radiologists’ 2025 census, with returns from every UK cancer centre and from most radiology departments, found that recruitment freezes have doubled in a year. In England, 57% of specialist cancer centres had a freeze, up from 24% the year before, and 39% of radiology departments were frozen too.
WHAT THE 2025 CENSUS FOUND
- Doctor shortfall: The UK has 32% fewer clinical radiologists than it needs, more than 2,300 posts, and 17% fewer clinical oncologists, more than 230.
- England freezes: 57% of cancer centres and 39% of radiology departments had a hiring freeze in 2025, each more than double the year before.
- Harm reported: Eight in 10 radiology leaders, and half of cancer leaders, said staff shortages were causing patients’ conditions to worsen.
- Treatment delays: Nine in 10 cancer leaders reported delays to radiotherapy or drug treatment, including chemotherapy, because of those shortages.
On 15 September the college sent a letter signed by 185 members and fellows to Karin Smyth, the health minister, asking her to stop trusts freezing consultant posts in cancer centres and radiology departments. The letter said 90% of cancer-centre leaders reported delays to treatment and 80% of radiology heads reported seeing patients get worse. It also warned that 257 clinical radiology residents and 46 clinical oncology residents were due to finish training, with 408 and 104 more the following year, and that frozen departments cannot offer them posts or take extra trainees.
Chronic shortages of clinical radiologists and clinical oncologists, who diagnose, monitor and treat cancer, are driving dangerous delays in diagnosing and treating the disease. Perversely, NHS hiring freezes for these doctors have doubled in the last year, making it even harder to keep patients safe.
Dr Stephen Harden, president, Royal College of Radiologists
The college points to a BMJ analysis that every month’s delay to starting cancer treatment can raise the risk of death by around 10%. Demand for complex scans, it says, is growing more than twice as fast as the radiologist workforce. Freezes hit smaller centres in poorer and rural areas harder, which is the same geography already sitting under the national 62-day average.
Urgent Referrals Have Risen About 20% in Four Years
The diagnosis drive is not a paper target. Community diagnostic centres, extra scanners and a higher 28-day bar have pulled more people onto urgent pathways, and September’s 300,367 Faster Diagnosis referrals show how large that funnel now is. Turabi’s 20% rise over four years is the load those centres were built to take. The conversion rate at the far end is still about 6%.
That arithmetic is why an improving all-clear time can travel with a stuck cancer-diagnosis time. Ruling cancer out is often a shorter path. Confirming it means more imaging, more biopsies, more pathology and a specialist meeting, and those are the steps the census says are short of doctors. When that work overruns, the 62-day clock has already been running from the day of referral. The 31-day clock, which starts only after a decision to treat, then looks healthier than the 62-day clock because the damage has already been done upstream.
Price’s warning about staff and kit sits on that same join. Extra diagnostic capacity without matching radiotherapy, theatre and oncology time does not retire the 9,490-patient gap. It changes who is holding the file when the 62 days run out. Williams put the same point from the other end: diagnosing people more quickly is of no use if the bottleneck has only moved.
The February Plan Still Aims at March 2029
The National Cancer Plan published on 3 February already treated March 2027 as a stepping stone. The government said the NHS would meet all cancer waiting time standards by 2029, including the 85% 62-day rate it has not met since 2015, and that 75% of people diagnosed from 2035 would be cancer-free or living well five years later, a claim it put at 320,000 extra lives over the life of the plan. An earlier staging post, 75% on the 62-day clock by March 2026, was already behind the 70.1% Cancer Research UK recorded for October 2025 to March 2026.
THE DATES ON THE CANCER CLOCK
- 2015: Last year the 85% 62-day standard was met.
- 1 October 2023: The NHS moves to three headline clocks, including a 28-day Faster Diagnosis Standard then set at 75%.
- 3 February 2026: The National Cancer Plan promises all three waiting-time standards by March 2029 and a 75% long-term survival aim from 2035.
- 1 April 2026: The Faster Diagnosis Standard rises to 80%.
- 12 November 2026: September figures show 70.7% on the 62-day clock and 76.2% on the 28-day clock.
- March 2027: Every trust is meant to reach 80% on the 62-day measure.
A Department of Health and Social Care spokesperson said cancer waiting times are moving in the right direction, with all three standards better than a year ago, and around 290,000 more people over the last year getting diagnosed on time or having cancer ruled out compared with the year before the election. The spokesperson said there is much more to do, and that the national cancer plan will help more people get diagnosed earlier and begin treatment sooner.
Cancer Research UK’s own projection of the 62-day series is colder. If recent trends hold, the rate reaches 77.6% by March 2029 if trends continue, 7.4 points under 85%, and the 85% line itself does not arrive until July 2032. Closing the gap by March 2029 would take about 46,900 extra on-time starts, or about 1,300 a month, on top of the path already baked in. The 80% date in March 2027 sits on that same slope, with September’s 70.7% as the last published step.
Wes Streeting, the health secretary, said at the plan’s launch that cancer survival should not come down to who won the lottery of life. The September files say the lottery is still running on two clocks at once, and that the patients who have cancer are the ones losing both.
Disclaimer: This article is news reporting on NHS waiting-time statistics, charity analysis and workforce census figures. It is informational only and is not medical advice, a diagnosis, or a guide to any individual’s treatment, referral or screening. Readers with symptoms, a suspected cancer referral or questions about their own care should speak to their GP, oncologist or another qualified clinician before making decisions. The percentages, counts and targets here reflect the official releases and analyses as published, and later monthly revisions can change them.
-
AUTO3 months agoThe Last Manual V-12 Lamborghini Cannot Come to America
-
BUSINESS3 months agoJBS’s Pilgrim’s Pride Bid Still Needs the 18 Percent
-
NEWS3 months agoRune Bets on Hillerød for His Achilles Comeback
-
NEWS3 months agoPermafrost Thaw Runs Fastest in Mountains, Not Arctic Soils
-
NEWS3 months agoMurphy Defends a British Open Title Nobody Keeps
-
BUSINESS3 months agoInfluencer Investors Trade Cash Fees for Illiquid Equity
-
NEWS3 months agoThe Roman Space Telescope Flies After Four Budget Fights
-
BUSINESS3 months agoRubicon Research Q1 Tests Its Specialty Pharma Bet
